AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11799368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10522838 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.25-4.0 mg preprandially)
Number of subjects: 0
Study 10522838 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.25-8.0 mg preprandially)
Number of subjects: 0
Study 10522838 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 0
Study 10522838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10522838 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5-4.0 mg preprandially)
Number of subjects: 0
Study 10522838 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylureas (glibenclamide, glipizide, gliclazide)
Number of subjects: 0
Study 7536152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks involving number comprehension
Number of subjects: 0
Study 7536152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks involving recognition of mathematical symbols
Number of subjects: 0
Study 7536152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks involving the calculation process
Number of subjects: 0
Study 7536152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks involving the spatial component
Number of subjects: 0
Study 7536152 — intervention group
Group type: COMPARATOR
Intervention: Rest periods
Number of subjects: 0
Study 7536152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks
Number of subjects: 0
Study 2039041 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 0
Study 2039041 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0
Study 2039041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 0
Study 2039041 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 7367848 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific hyposensitization treatment with semi-depot extracts
Number of subjects: 821
Study 7367848 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific hyposensitization treatment for asthma
Number of subjects: 821
Study 7367848 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific hyposensitization treatment for rhinitis
Number of subjects: 821
Study 7367848 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific hyposensitization treatment for conjunctivitis
Number of subjects: 821
Study 7367848 — intervention group
Group type: EXPERIMENTAL
Intervention: Second and third courses of treatment
Number of subjects: 821
Study 7367848 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized allergic reactions during hyposensitization
Number of subjects: 821
Study 7367848 — intervention group
Group type: EXPERIMENTAL
Intervention: Local reactions during hyposensitization
Number of subjects: 821
Study 7367848 — intervention group
Group type: COMPARATOR
Intervention: Global results of 409 hyposensitization treatments by outside practitioners
Number of subjects: 821
Study 31053570 — intervention group
Group type: EXPERIMENTAL
Intervention: pdFVIII
Number of subjects: 0
Study 31053570 — intervention group
Group type: EXPERIMENTAL
Intervention: FL-rFVIII
Number of subjects: 0
Study 31053570 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pdFVIII and FL-rFVIII
Number of subjects: 0
Study 29089038 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200 mg) and ascorbic acid (2 g) intravenously, administered 2 hours before, and at 10 and 18 hours after contrast infusion
Number of subjects: 124
Study 29089038 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 124
Study 29089038 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine and ascorbic acid
Number of subjects: 124
Study 25582984 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose levonorgestrel (LNG) and ethinyl estradiol (EE) contraceptive patch (CP, Twirla™)
Number of subjects: 1328
Study 25582984 — intervention group
Group type: COMPARATOR
Intervention: Low-dose combination oral contraceptive (COC)
Number of subjects: 1328
Study 25582984 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory assessments for both groups
Number of subjects: 1328
Study 23350584 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 201
Study 23350584 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple lines of trastuzumab
Number of subjects: 201
Study 23350584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib after trastuzumab
Number of subjects: 201
Study 23350584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib after diagnosis of brain metastases (BM)
Number of subjects: 201
Study 23350584 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive estrogen receptor (ER) status
Number of subjects: 201
Study 21314437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcaftadine ophthalmic solution 0.25%
Number of subjects: 0
Study 21314437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcaftadine ophthalmic solution (various concentrations 0.05%-0.5%)
Number of subjects: 0
Study 21314437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcaftadine 0.25% ophthalmic solution
Number of subjects: 0
Study 21314437 — intervention group
Group type: COMPARATOR
Intervention: Tears Naturale II (placebo)
Number of subjects: 0
Study 19223168 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-loading with 500 mL of 6% hetastarch intravenously
Number of subjects: 46
Study 19223168 — intervention group
Group type: COMPARATOR
Intervention: Co-loading with 500 mL of 6% hetastarch intravenously
Number of subjects: 46
Study 17415637 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin
Number of subjects: 20
Study 17415637 — intervention group
Group type: COMPARATOR
Intervention: Oral omeprazole without erythromycin
Number of subjects: 20
Study 15155436 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac patch
Number of subjects: 120
Study 15155436 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 120
Study 11589866 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.0015%
Number of subjects: 801
Study 11589866 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 801
Study 11589866 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 801
Study 11589866 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 801
Study 9699197 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen gel (group A)
Number of subjects: 39
Study 9699197 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (group P)
Number of subjects: 39
Study 8076921 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic calcitonin
Number of subjects: 25
Study 8076921 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (less than one hundredth of the recommended dose of porcine calcitonin)
Number of subjects: 25
Study 2676651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 545
Study 2676651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg/day + slow-release metoprolol 200 mg/day
Number of subjects: 545
Study 2676651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus metoprolol
Number of subjects: 545
Study 2676651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus metoprolol plus a third drug
Number of subjects: 545
Study 356233 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (10 mg/kg body weight for a total of 25 times) in combination with prednisone and azathioprine
Number of subjects: 40
Study 356233 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of prednisone and azathioprine
Number of subjects: 40
Study 31187552 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (pelvic floor muscle exercises, bladder training, fluid and constipation management)
Number of subjects: 53
Study 31187552 — intervention group
Group type: COMPARATOR
Intervention: Control condition (bladder diary self‐monitoring)
Number of subjects: 53
Study 28214220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hanging-drop technique in lateral recumbency (LHDo)
Number of subjects: 45
Study 28214220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hanging-drop technique in sternal recumbency (SHDo)
Number of subjects: 45
Study 28214220 — intervention group
Group type: COMPARATOR
Intervention: Running-drip method (SRDi)
Number of subjects: 45
Study 25797356 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11/CDDP (CPT‐11, 60 mg/m²; CDDP, 30 mg/m², q2w)
Number of subjects: 163
Study 25797356 — intervention group
Group type: COMPARATOR
Intervention: CPT‐11 (150 mg/m², q2w)
Number of subjects: 163
Study 25797356 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11/CDDP
Number of subjects: 163
Study 25797356 — intervention group
Group type: COMPARATOR
Intervention: CPT‐11
Number of subjects: 163
Study 23590571 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (100 mg daily)
Number of subjects: 7000
Study 23590571 — intervention group
Group type: EXPERIMENTAL
Intervention: L-selenomethionine (200 μg daily)
Number of subjects: 7000
Study 23590571 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 7000
Study 21533333 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic, strength and flexibility exercises for 24 weeks
Number of subjects: 42
Study 21533333 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 19661114 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal left ventricular lead positions (LV‐Ps)
Number of subjects: 567
Study 16756046 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and clinical pathway for treatment of hypoglycemia
Number of subjects: 65
Study 16756046 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for hypoglycemia
Number of subjects: 65
Study 15365384 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected vision after 3 hours without refractive correction
Number of subjects: 22
Study 15365384 — intervention group
Group type: EXPERIMENTAL
Intervention: Grating acuity after 3 hours without refractive correction
Number of subjects: 22
Study 15365384 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive error measurement using noncycloplegic autorefraction
Number of subjects: 22
Study 11726433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 55
Study 11726433 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 55
Study 9427777 — intervention group
Group type: EXPERIMENTAL
Intervention: D-galactose (1.5 g/kg body weight per day)
Number of subjects: 193
Study 9427777 — intervention group
Group type: COMPARATOR
Intervention: D-glucose containing electrolyte infusions (control group)
Number of subjects: 193
Study 9427777 — intervention group
Group type: EXPERIMENTAL
Intervention: D-galactose treatment
Number of subjects: 193
Study 8302686 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 4 g/70 kg
Number of subjects: 9
Study 8302686 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin 5 g/70 kg
Number of subjects: 9
Study 3461023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate dentifrice
Number of subjects: 7
Study 3461023 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 7
Study 29257028 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoliase (1.25 U)
Number of subjects: 163
Study 29257028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 27322401 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 271
Study 27322401 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinical evaluation alone)
Number of subjects: 271
Study 24942277 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 (80‐120 mg/day on days 1‐28 every 42 days; four courses)
Number of subjects: 1518
Study 24942277 — intervention group
Group type: COMPARATOR
Intervention: UFT/LV (UFT: 300‐600 mg/day and LV: 75 mg/day on days 1‐28 every 35 days; five courses)
Number of subjects: 1518
Study 21922164 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturation measured by SL‐ASIA
Number of subjects: 847
Study 21922164 — intervention group
Group type: EXPERIMENTAL
Intervention: Education in the US
Number of subjects: 847
Study 21922164 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age of arrival (0-5 years)
Number of subjects: 847
Study 21922164 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age of arrival (6-10 years)
Number of subjects: 847
Study 21922164 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-identified as Americans
Number of subjects: 847
Study 21922164 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal preference of Asian/American food in restaurants
Number of subjects: 847
Study 20804245 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy
Number of subjects: 127
Study 20804245 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered supportive emotion focused therapy
Number of subjects: 127
Study 18723437 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg twice daily
Number of subjects: 109
Study 18723437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 16753969 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole
Number of subjects: 148
Study 12830992 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (angiotensin II antagonist)
Number of subjects: 103
Study 11956505 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg every 12 hours)
Number of subjects: 7
Study 11956505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9591486 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy, bone densitometry
Number of subjects: 241
Study 9591486 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal population)
Number of subjects: 241
Study 7846209 — intervention group
Group type: EXPERIMENTAL
Intervention: Single morphine pretreatment (15 mg/70 kg IM)
Number of subjects: 40
Study 7846209 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated morphine pretreatment (two doses of 15 mg/70 kg IM spaced 24 h apart)
Number of subjects: 40
Study 7846209 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid abuse history
Number of subjects: 40
Study 7846209 — intervention group
Group type: COMPARATOR
Intervention: Nonabusers
Number of subjects: 40
Study 3411088 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% spironolactone cream
Number of subjects: 6
Study 3411088 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 6
Study 31418989 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine 54 mg + hydrocortisone 10 mg
Number of subjects: 21
Study 31418989 — intervention group
Group type: COMPARATOR
Intervention: placebo (lactose 54 mg + lactose 10 mg)
Number of subjects: 21
Study 31186388 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 83
Study 31186388 — intervention group
Group type: COMPARATOR
Intervention: Custom foot orthotics (CFO)
Number of subjects: 83
Study 27451294 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sachets of sodium picosulfate plus magnesium sulfate (P/MC)
Number of subjects: 198
Study 27451294 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L of polyethylene glycol (PEG)
Number of subjects: 198
Study 27451294 — intervention group
Group type: COMPARATOR
Intervention: Clear fluids only
Number of subjects: 198
Study 25808980 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 34
Study 25808980 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 34
Study 23506356 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic cohesive polydensified matrix (CPM)
Number of subjects: 20
Study 23506356 — intervention group
Group type: COMPARATOR
Intervention: Biphasic nonanimal stabilized hyaluronic acid (NASHA)
Number of subjects: 20
Study 21679977 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy for prostate cancer
Number of subjects: 1244
Study 18507878 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange and blackcurrant juice (500 ml/d)
Number of subjects: 48
Study 18507878 — intervention group
Group type: COMPARATOR
Intervention: Reference beverage (sugar drink)
Number of subjects: 48
Study 18507878 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (15 mg RRR-alpha-tocopherol/d)
Number of subjects: 48
Study 18507878 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice + Vitamin E
Number of subjects: 48
Study 18507878 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice + Placebo
Number of subjects: 48
Study 18507878 — intervention group
Group type: COMPARATOR
Intervention: Reference beverage + Vitamin E
Number of subjects: 48
Study 18507878 — intervention group
Group type: COMPARATOR
Intervention: Reference beverage + Placebo
Number of subjects: 48
Study 16430782 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ care for pneumonia in nursing homes
Number of subjects: 14
Study 16430782 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making involvement
Number of subjects: 14
Study 15327191 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction program (Cigota)
Number of subjects: 200
Study 15327191 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 200
Study 11535207 — intervention group
Group type: EXPERIMENTAL
Intervention: monophasic desogestrel/ethinylestradiol (DG/EE)
Number of subjects: 37
Study 11535207 — intervention group
Group type: EXPERIMENTAL
Intervention: triphasic levonorgestrel/ethinylestradiol (LNG/EE)
Number of subjects: 37
Study 9407254 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% glucose and fructose solution at a rate of approximately 60 g/hr
Number of subjects: 30
Study 9407254 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificially flavored solution)
Number of subjects: 30
Study 8218764 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) 10 mg, three daily doses, vo
Number of subjects: 20
Study 8218764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride (CTP) 1 mg, three daily doses, vo
Number of subjects: 20
Study 3506191 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding their own maternity case notes
Number of subjects: 246
Study 3506191 — intervention group
Group type: COMPARATOR
Intervention: Standard co‐operation card
Number of subjects: 246
Study 31927311 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the nucleus accumbens (NAcc)
Number of subjects: 8
Study 31927311 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the subgenual anterior cingulate cortex (subgenual ACC)
Number of subjects: 8
Study 31927311 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of DBS
Number of subjects: 8
Study 31927311 — intervention group
Group type: COMPARATOR
Intervention: Accidental switch off of DBS
Number of subjects: 8
Study 31056776 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 99
Study 31056776 — intervention group
Group type: COMPARATOR
Intervention: 0 AADs
Number of subjects: 99
Study 31056776 — intervention group
Group type: COMPARATOR
Intervention: 1 AAD
Number of subjects: 99
Study 31056776 — intervention group
Group type: COMPARATOR
Intervention: ≥2 AADs
Number of subjects: 99
Study 29196484 — intervention group
Group type: EXPERIMENTAL
Intervention: Samryungbaekchulsan (SRS) with Otilonium bromide (OB)
Number of subjects: 80
Study 29196484 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Samryungbaekchulsan (SRS) with Otilonium bromide (OB)
Number of subjects: 80
Study 26320838 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining
Number of subjects: 125
Study 26320838 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 125
Study 26320838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/low-glycaemic-index energy-restricted diet
Number of subjects: 125
Study 26320838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gait retraining, progressive resistance training, and high-protein/low-glycaemic-index diet
Number of subjects: 125
Study 26320838 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle-advice control group
Number of subjects: 125
Study 23124784 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral-pH, low-glucose degradation product peritoneal dialysis fluids with 35 mM lactate
Number of subjects: 37
Study 23124784 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral-pH, low-glucose degradation product peritoneal dialysis fluids with 34 mM bicarbonate
Number of subjects: 37
Study 23124784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate peritoneal dialysis fluid
Number of subjects: 37
Study 23124784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate peritoneal dialysis fluid
Number of subjects: 37
Study 22104981 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 0
Study 22104981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19770284 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (6 mg/kg q12h on day 1, then 4 mg/kg q12h)
Number of subjects: 20
Study 19770284 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (200 mg on day 1, then 100 mg every 24 h)
Number of subjects: 20
Study 16797271 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L of Belzer solution
Number of subjects: 43
Study 16797271 — intervention group
Group type: COMPARATOR
Intervention: 2 L of Collins solution and 2 L of Belzer solution
Number of subjects: 43
Study 16797271 — intervention group
Group type: COMPARATOR
Intervention: 3 L of Collins and 1 L of Belzer solution
Number of subjects: 43
Study 15271637 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions about dementia diagnosis and management
Number of subjects: 127
Study 10769856 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide/60% oxygen
Number of subjects: 22
Study 10769856 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 22